Adagene Announces Poster Presentation On Optimal Dose Selection For Masked Anti-CTLA-4 SAFEbody ADG126 At Upcoming Society For Immunotherapy Of Cancer 38th Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Adagene Inc. (NASDAQ:ADAG) has announced its poster presentation at the Society for Immunotherapy of Cancer 38th Annual Meeting. The presentation will focus on the optimal dose selection for its masked anti-CTLA-4 SAFEbody ADG126. The data reinforces the mechanism of action and selection of 10 mg/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort.
October 12, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adagene's announcement of its presentation at the SITC Annual Meeting could potentially increase investor interest in the company. The presentation will focus on the optimal dose selection for its ADG126, which could be a significant development in the company's product pipeline.
The announcement of Adagene's presentation at the SITC Annual Meeting could potentially increase investor interest in the company. The focus of the presentation on the optimal dose selection for its ADG126 could be seen as a significant development in the company's product pipeline, which could positively impact the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100